TY - JOUR
T1 - Is Gly16Arg β2 Receptor Polymorphism Related to Impulse Oscillometry in a Real-Life Asthma Clinic Setting?
AU - Jabbal, Sunny
AU - Manoharan, Arvind
AU - Lipworth, Joseph
AU - Anderson, William
AU - Short, Philip
AU - Lipworth, Brian
N1 - Dr William Anderson has received support from Astra Zeneca and Chiesi to attend educational meetings. Dr Brian Lipworth has received previous grant support from the Chief Scientist Office, Scotland to evaluate effects of propranolol in patients with persistent-treated asthma. BJL has also received unrestricted grant support from Chiesi, Meda, Almirall and Teva to evaluate small airways in persistent asthma and COPD, as well as multi-centre pharmaceutical support from Astra Zeneca, Teva, Janssen and Roche. In addition, BJL has received personal payment for consultancy and advisory boards with the following pharmaceutical companies: Astra Zeneca, Chiesi, Teva, Boehringer Ingelheim and Meda. BJL has also received personal payment for giving speaker talks with Chiesi, Teva, Meda and Mitsubishi Tanabe as well as support to attend educational meetings from Chiesi, Boehringer Ingelheim and Teva.
PY - 2016/4
Y1 - 2016/4
N2 - Purpose: We evaluated whether Gly16Arg beta2-receptor genotype relates to impulse oscillometry (IOS) in a real-life clinic setting. Methods: Patients with persistent asthma taking inhaled corticosteroid ± long-acting beta-agonist (ICS ± LABA) were evaluated. We compared genotype groups comprising either no Arg copies (i.e. GlyGly) versus one or two Arg copies (i.e. ArgArg or ArgGly). IOS outcomes included total airway resistance at 5 Hz (R5), central airway resistance at 20 Hz (R20), peripheral airway resistance (R5–R20), reactance at 5 Hz, area under reactance curve (AX) and resonant frequency (RF). In addition, we recorded ACQ-5 and salbutamol use.Results: One hundred and twelve ICS-treated asthmatic patients (mean ICS dose 1238 µg/day), mean age 43 years, ACQ 2.34, FEV1 82 %, R5 177 % were identified—89 were also taking LABA. 61 patients were GlyGly, while 14 were ArgArg and 37 were ArgGly. There were no significant differences in IOS outcomes, ACQ or salbutamol use between the genotypes. The allelic risk (as odds ratio) for less well-controlled asthma (as ACQ > 1.5) was 1.1 (95 % CI 0.72–1.68) in relation to each Arg copy with a corresponding odds ratio for abnormal R5–R20 > 0.07kPA/l.s being 0.91 (95 % CI 0.57–1.44). 71 % of patients had an ACQ > 1.5 in the GlyGly group, versus 67 % in GlyArg/ArgArg group, with corresponding figures for abnormal R5–R20 > 0.07 kPa/l.s being 69 versus 73 %. Conclusion: In a real-life clinic setting for patients with poorly controlled persistent asthma taking ICS ± LABA, we found no evidence of any relationship of Gly16Arg to IOS, ACQ or salbutamol use.
AB - Purpose: We evaluated whether Gly16Arg beta2-receptor genotype relates to impulse oscillometry (IOS) in a real-life clinic setting. Methods: Patients with persistent asthma taking inhaled corticosteroid ± long-acting beta-agonist (ICS ± LABA) were evaluated. We compared genotype groups comprising either no Arg copies (i.e. GlyGly) versus one or two Arg copies (i.e. ArgArg or ArgGly). IOS outcomes included total airway resistance at 5 Hz (R5), central airway resistance at 20 Hz (R20), peripheral airway resistance (R5–R20), reactance at 5 Hz, area under reactance curve (AX) and resonant frequency (RF). In addition, we recorded ACQ-5 and salbutamol use.Results: One hundred and twelve ICS-treated asthmatic patients (mean ICS dose 1238 µg/day), mean age 43 years, ACQ 2.34, FEV1 82 %, R5 177 % were identified—89 were also taking LABA. 61 patients were GlyGly, while 14 were ArgArg and 37 were ArgGly. There were no significant differences in IOS outcomes, ACQ or salbutamol use between the genotypes. The allelic risk (as odds ratio) for less well-controlled asthma (as ACQ > 1.5) was 1.1 (95 % CI 0.72–1.68) in relation to each Arg copy with a corresponding odds ratio for abnormal R5–R20 > 0.07kPA/l.s being 0.91 (95 % CI 0.57–1.44). 71 % of patients had an ACQ > 1.5 in the GlyGly group, versus 67 % in GlyArg/ArgArg group, with corresponding figures for abnormal R5–R20 > 0.07 kPa/l.s being 69 versus 73 %. Conclusion: In a real-life clinic setting for patients with poorly controlled persistent asthma taking ICS ± LABA, we found no evidence of any relationship of Gly16Arg to IOS, ACQ or salbutamol use.
KW - Asthma
KW - Beta-2 receptor
KW - Genotype
KW - Impulse oscillometry
UR - http://www.scopus.com/inward/record.url?scp=84958254598&partnerID=8YFLogxK
U2 - 10.1007/s00408-016-9848-5
DO - 10.1007/s00408-016-9848-5
M3 - Article
C2 - 26880163
SN - 0341-2040
VL - 194
SP - 267
EP - 271
JO - Lung
JF - Lung
IS - 2
ER -